Diverse elements have combined in recent years to make Clinical Outcome Assessments (COAs), and particularly Patient Reported Outcomes (PROs), important criteria for various health authorities in the evaluation of new therapeutic strategies. So Olivier Chassany has written this COAs white paper in order to deal with their importance in the evaluation by health authorities.
Why is this and what are the consequences for evaluation of new drugs in clinical development programs? When should COA endpoints be considered for inclusion in a new drug development program?
By Olivier Chassany, Professor of PROs & Clinical Endpoints research at the University Paris-Diderot, France
TO READ THE WHITE PAPER, CLICK BELOW :
[tag url=”https://kayentis.com/wp-content/uploads/2016/12/coa_important_criteria_health_authorities_kayentiswhitepaper.pdf” event=”click dossier ECoa”]
